Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials
- PMID: 26466871
- DOI: 10.1016/S0140-6736(15)60031-9
Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials
Abstract
Background: Most totally blind people have non-24-hour sleep-wake disorder (non-24), a rare circadian rhythm disorder caused by an inability of light to reset their circadian pacemaker. In two consecutive placebo-controlled trials (SET and RESET), we assessed safety and efficacy (in terms of circadian entrainment and maintenance) of once-daily tasimelteon, a novel dual-melatonin receptor agonist.
Methods: We undertook the placebo-controlled, randomised, double-masked trials in 27 US and six German clinical research centres and sleep centres. We screened totally blind adults (18-75 years of age), who were eligible for the randomisation phase of SET if they had a non-24-hour circadian period (τ) of 24·25 h or longer (95% CI greater than 24·0 and up to 24·9 h), as calculated from measurements of urinary 6-sulphatoxymelatonin rhythms. For SET, we used block randomisation to assign patients (1:1) to receive tasimelteon (20 mg) or placebo every 24 h at a fixed clock time 1 h before target bedtime for 26 weeks. Patients who entered the open-label group receiving tasimelteon in SET or who did not meet the SET inclusion criteria but did meet the RESET inclusion criteria were screened for RESET. A subset of the patients who entered the open-label group before the RESET study and who had eligible τ values were screened for RESET after completing the open-label treatment. In RESET, we withdrew tasimelteon in a randomised manner (1:1) in patients who responded (ie, entrained) after a tasimelteon run-in period. Entrainment was defined as having τ of 24·1 h or less and a 95% CI that included 24·0 h. In SET, the primary endpoint was the proportion of entrained patients, assessed in the intention-to-treat population. The planned step-down primary endpoint assessed the proportion of patients who had a clinical response (entrainment at month 1 or month 7 plus clinical improvement, measured by the Non-24 Clinical Response Scale). In RESET, the primary endpoint was the proportion of non-entrained patients, assessed in the intention-to-treat population. Safety assessments included adverse events and clinical laboratory measures, assessed in all treated patients. These trials are registered with ClinicalTrials.gov, numbers NCT01163032 and NCT01430754.
Findings: Between Aug 25, 2010, and July 5, 2012, we screened 391 totally blind patients for SET, of whom 84 (22%) were assigned to receive tasimelteon (n=42) or placebo (n=42). Two patients in the tasimelteon group and four in the placebo group discontinued the study before τ was measured, due to adverse events, withdrawal of consent, and a protocol deviation. Circadian entrainment occurred in eight (20%) of 40 patients in the tasimelteon group compared with one (3%) of 38 patients in the placebo group at month 1 (difference 17%, 95% CI 3·2-31·6; p=0·0171). Nine (24%) of 38 patients showed a clinical response, compared with none of 34 in the placebo group (difference 24%, 95% CI 8·4-39·0; p=0·0028). Between Sept 15, 2011, and Oct 4, 2012, we screened 58 patients for eligibility in RESET, 48 (83%) of whom had τ assessed and entered the open-label tasimelteon run-in phase. 24 (50%) patients entrained, and 20 (34%) were enrolled in the randomisation phase. Two (20%) of ten patients who were withdrawn to placebo remained entrained compared with nine (90%) of ten who continued to receive tasimelteon (difference 70%, 95% CI 26·4-100·0; p=0·0026). No deaths were reported in either study, and discontinuation rates due to adverse events were comparable between the tasimelteon (3 [6%] of 52 patients) and placebo (2 [4%] of 52 patients) treatment courses. The most common side-effects associated with tasimelteon in SET were headache (7 [17%] of 42 patients given tasimelteon vs 3 [7%] of 42 patients given placebo), elevated liver enzymes (4 [10%] vs 2 [5%]), nightmares or abnormal dreams (4 [10%] vs none), upper respiratory tract infection (3 [7%] vs none], and urinary tract infections (3 [7%] vs 1 [2%]).
Interpretation: Once-daily tasimelteon can entrain totally blind people with non-24; however, continued tasimelteon treatment is necessary to maintain these improvements.
Funding: Vanda Pharmaceuticals.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Comment in
-
Entraining the free-running circadian clocks of blind people.Lancet. 2015 Oct 31;386(10005):1713. doi: 10.1016/s0140-6736(15)61451-9. Lancet. 2015. PMID: 26554081 No abstract available.
Similar articles
-
Tasimelteon for the treatment of non-24-hour sleep-wake disorder.Drugs Today (Barc). 2015 Jan;51(1):29-35. doi: 10.1358/dot.2015.51.1.2258364. Drugs Today (Barc). 2015. PMID: 25685859 Review.
-
Tasimelteon: a melatonin receptor agonist for non-24-hour sleep-wake disorder.Ann Pharmacother. 2014 Dec;48(12):1636-41. doi: 10.1177/1060028014550476. Epub 2014 Sep 9. Ann Pharmacother. 2014. PMID: 25204464 Review.
-
Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals.CNS Drugs. 2016 May;30(5):461-8. doi: 10.1007/s40263-016-0330-y. CNS Drugs. 2016. PMID: 27003694 Review.
-
Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials.Lancet. 2009 Feb 7;373(9662):482-91. doi: 10.1016/S0140-6736(08)61812-7. Epub 2008 Dec 4. Lancet. 2009. PMID: 19054552 Clinical Trial.
-
Tasimelteon for treating non-24-h sleep-wake rhythm disorder.Expert Opin Pharmacother. 2019 Jun;20(9):1065-1073. doi: 10.1080/14656566.2019.1603293. Epub 2019 Apr 16. Expert Opin Pharmacother. 2019. PMID: 30990759
Cited by
-
Circadian neurogenetics and its implications in neurophysiology, behavior, and chronomedicine.Neurosci Biobehav Rev. 2024 Feb;157:105523. doi: 10.1016/j.neubiorev.2023.105523. Epub 2023 Dec 22. Neurosci Biobehav Rev. 2024. PMID: 38142983 Review.
-
The Effect of Blindness on Biological Rhythms and the Consequences of Circadian Rhythm Disorder.Turk J Ophthalmol. 2023 Apr 20;53(2):111-119. doi: 10.4274/tjo.galenos.2022.59296. Turk J Ophthalmol. 2023. PMID: 37089032 Free PMC article.
-
From Bench to Bedside and Back Again: Translating Circadian Science to Medicine.J Biol Rhythms. 2023 Apr;38(2):125-130. doi: 10.1177/07487304221142743. Epub 2022 Dec 30. J Biol Rhythms. 2023. PMID: 36583523 Free PMC article. No abstract available.
-
Keeping an eye on circadian time in clinical research and medicine.Clin Transl Med. 2022 Dec;12(12):e1131. doi: 10.1002/ctm2.1131. Clin Transl Med. 2022. PMID: 36567263 Free PMC article. Review.
-
Once-daily tasimelteon (VEC-162) for jet lag following transmeridian travel: A multicenter, randomized, double-blind, placebo-controlled trial.Front Neurol. 2022 Sep 15;13:901467. doi: 10.3389/fneur.2022.901467. eCollection 2022. Front Neurol. 2022. PMID: 36188367 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources